‘Time to Make a Warren Buffett Move,’ Says Top Investor About Novo Nordisk Stock
Along with the rest of the market, Novo Nordisk (NYSE:NVO) has been sinking this year – with losses approaching 30% year-to-date. The skid for the Danish biopharma company started awhile back, and the company’s share price has lost over half its value since reaching a peak last summer.
Stay Ahead of the Market:
The appetite for the company’s injectable GLP-1 obesity drug,